Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-SARS-CoV-2 Oral Vaccine
- Development stage
- Preclinical
- Lead developer
- CHAIN Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Anti-SARS-CoV-2 Oral Vaccine is an investigational oral COVID-19 vaccine being developed by CHAIN Biotech using its CADD platform, which employs engineered non-pathogenic *Clostridium butyricum* as a live bacterial spore and vector for lower gastrointestinal delivery of SARS-CoV-2 antigens. The intended mechanism is oral presentation of SARS-CoV-2 antigens to induce protective mucosal and systemic immune responses against COVID-19. Publicly available pipeline information identifies the program and its modality and target class, but does not disclose a specific product code, antigen composition, adjuvant, dosage form details beyond oral administration, or a defined clinical phase.
- Other names
- anti-SARS-CoV-2 oral vaccineanti-SARS-CoV2 oral vaccineanti-SARS-CoV 2 oral vaccineAnti-COVID-19 oral vaccineAnti-COVID19 oral vaccineAnti-COVID 19 oral vaccineAnti-SARS-CoV-2 CADD oral vaccineAnti-SARS-CoV2 CADD oral vaccineAnti-SARS-CoV 2 CADD oral vaccine
Beyond the preview
Go deeper on Anti-SARS-CoV-2 Oral Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-SARS-CoV-2 Oral Vaccine.